Medi0562
Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials UnitPhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 59/ 100
Competitive context
440 Active assets in the Ovarian Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olaparib Shandong University | Phase 4 | BB |
Inno-206 Genmab | Phase 3 | BB |
Irinotecan ARCAGY/ GINECO GROUP | Phase 4 | BB |
Carboplatin Fudan University | Phase 4 | BB |
(+)-VINCRISTINE ARCAGY/ GINECO GROUP | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →